Innovative strategies for stabilization of therapeutic peptides in aqueous formulations
PhD ceremony: Ms. C. Avanti, 16.15 uur, Academiegebouw, Broerstraat 5, Groningen
Dissertation: Innovative strategies for stabilization of therapeutic peptides in aqueous formulations
Promotor(s): prof. H.W. Frijlink
Faculty: Mathematics and Natural Sciences
Every year 166 000 women die of bleeding after child birth, and more than 50% of these deaths occur in sub-Saharan Africa (Clyburn et. al., 2007). Oxytocin, a nonapeptide which is the drug of first choice to treat bleeding after childbirth or post-partum hemorrhage (PPH). Although the availability of this drug has greatly declined maternal mortality rates in the developed world, PPH remains a leading cause of maternal mortality elsewhere. Current commercial formulations of oxytocin are insufficiently heat-stable to withstand tropical conditions.
The starting point for the research of Christina Avanti was the insufficient access of mothers in the tropical developing countries to liquid oxytocin formulations for injection which are heat stable, affordable, and simple to use. In her research she has been able to find oxytocin formulations with an improved stablility. These formulations are based on combinations of divalent cations (calcium, zinc or magnesium) and carboxylate buffers (e.g. citrate, malonate or aspartate). Furthermore the degradation pathways of oxytocin were investigated and further understanding of the mechanism by which the cations and buffers stabilize the oxytocin was gained.
Last modified: | 13 March 2020 01.01 a.m. |
More news
-
04 July 2025
University of Groningen awards different prizes during Ceremony of Merits
The UG awarded different prizes to excellent researchers and students during the Ceremony of Merits on 4 July 2025.
-
03 July 2025
Erik Heeres receives RUG Impact Innovator Excellence Award
During the RUG Ventures Innovation Day, Prof. Erik Heeres of the Faculty of Science and Engineering (RUG) was awarded the Impact Innovator Excellence Award.
-
02 July 2025
€ 30 million investment for UG spin-off Portal Biotech
Portal Biotech, a pioneer in nanopore-based protein identification and sequencing technology, has raised € 30 million in Series A funding. The funding will support commercial rollout and team growth.